Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00651963 |
Gather additional efficacy and safety (pharmacovigilance) information in the usual daily care in patients with Dyslipidemia on ezetimibe under real conditions in Colombia associated with statins.
Condition | Intervention | Phase |
---|---|---|
Lipid Metabolism Disorder |
Drug: ezetimibe |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia |
Enrollment: | 80 |
Study Start Date: | September 2004 |
Primary Completion Date: | March 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2008_007, MK0653-141 |
Study First Received: | March 31, 2008 |
Last Updated: | March 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00651963 History of Changes |
Health Authority: | Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos |
Antimetabolites Metabolic Diseases Antilipemic Agents Ezetimibe Anticholesteremic Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Metabolic Disorder Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Metabolic Diseases Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Ezetimibe Anticholesteremic Agents Pharmacologic Actions Dyslipidemias Lipid Metabolism Disorders |